For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Research and development | 109,818 | |||
| General and administrative | 33,186 | |||
| Total operating expenses | 143,004 | |||
| Loss from operations | -143,004 | |||
| Other income, net | 13,536 | |||
| Net loss | -129,468 | |||
| Unrealized gain on investments | 407 | |||
| Comprehensive loss | -129,061 | |||
| Basic EPS | -1.47 | |||
| Diluted EPS | -1.47 | |||
| Basic Average Shares | 87,793,801 | |||
| Diluted Average Shares | 87,793,801 | |||
Oric Pharmaceuticals, Inc. (ORIC)
Oric Pharmaceuticals, Inc. (ORIC)